Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roivant Sciences ( (ROIV) ) has provided an update.
On September 17, 2025, Roivant Sciences announced positive results from the Phase 3 VALOR study of brepocitinib in dermatomyositis, marking the first successful 52-week placebo-controlled trial for this condition. The study demonstrated significant improvements in patients, with brepocitinib showing a clinically meaningful response compared to placebo on both primary and secondary endpoints, and a consistent safety profile. This breakthrough positions brepocitinib as a potential impactful treatment option for dermatomyositis, with an NDA filing planned for the first half of 2026.
The most recent analyst rating on (ROIV) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.
Spark’s Take on ROIV Stock
According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.
Roivant Sciences’ overall stock score is driven by a strong technical outlook and positive earnings call sentiment, reflecting strategic advancements and a robust financial position. However, financial performance and valuation remain weak due to ongoing losses and negative cash flows, typical challenges in the biotechnology sector.
To see Spark’s full report on ROIV stock, click here.
More about Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on accelerating the development and commercialization of medicines, with a pipeline that includes brepocitinib, a TYK2 and JAK1 inhibitor for treating dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. The company creates subsidiaries to develop and commercialize its medicines and also incubates discovery-stage companies and health technology startups.
Average Trading Volume: 6,351,299
Technical Sentiment Signal: Buy
Current Market Cap: $9.53B
Learn more about ROIV stock on TipRanks’ Stock Analysis page.